鼻咽癌放化疗致慢性鼻窦炎患者症状困扰分析

Analysis of symptom distress in nasopharyngeal carcinoma patients experiencing chemoradiotherapy induced chronic sinusitis

目的探讨鼻咽癌放化疗致慢性鼻窦炎患者症状困扰现状并分析其影响因素,为临床制定护理方案提供参考。方法以便利抽样法收集广西某三级甲等综合医院放疗科门诊复查的鼻咽癌放化疗致慢性鼻窦炎患者193例为研究对象,采用一般资料调查表、鼻腔鼻窦结局测试22特异性量表、公众健康积极指数量表、中文版预后和治疗认知问卷进行横断面调查,采用多元线性回归分析患者症状困扰的相关影响因素。结果鼻咽癌放化疗致慢性鼻窦炎患者症状困扰得分为(27.05±6.37)分。多元线性回归分析显示,鼻咽冲洗依从性、健康积极度得分、预后关注度得分为鼻咽癌放化疗致慢性鼻窦炎患者症状困扰的预测因素(均P<0.05)。结论鼻咽癌放化疗致慢性鼻窦炎患者症状困扰处于轻度水平,且普遍存在。医疗人员亟需对鼻咽癌放化疗致慢性鼻窦炎患者制定针对性护理干预措施,以减轻症状负担,提高生存质量。

Objective To investigate the current situation of symptom distress in nasopharyngeal carcinoma patients experiencing chemoradiotherapy induced chronic sinusitis,and analyze its influencing factors,so as to provide a reference for developing relevant nursing countermeasures.Methods A total of 193 nasopharyngeal carcinoma patients experiencing chemoradiotherapy induced chronic sinusitis were selected in the outpatient clinic of radiotherapy department of a tertiary general hospital in Guangxi by conve-nience sampling method,then they were cross-sectionally investigated by utilizing a general information questionnaire,the Sino-Nasal Outcome Test,the Consumer Health Activation Index,and the Chinese version Prognosis and Treatment Perception Questionnaire.Finally,multiple linear regression analysis was conducted to analyze the influencing factors of the participants′symptom distress.Results The participants scored(27.05±6.37)in symptom distress.Multiple linear regression analysis showed that,nasopharyngeal flushing compliance,health positivity score,and prognostic concern score were predictors of symptom distress in nasopharyngeal carcinoma patients experiencing chemoradiotherapy induced chronic sinusitis(all P<0.05).Conclusion Symptom distress in nasopharyngeal carcinoma patients experiencing chemoradiotherapy induced chronic sinusitis is at a mild level and prevalent.It is urgent for medical staff to develop targeted nursing interventions to alleviate patients′burden of symptoms,and improve their quality of life.